As a naturally occurring post-transcriptional gene regulatory mechanism, RNAi is currently a very promising therapy due to its precise multi-targeted gene silencing. Although the RNAi approach is very favorable and promising, the inherent low half-life and instability of siRNAs in biological systems do not allow direct administration of siRNAs to achieve the desired results. The preparation of siRNA-based chimeric molecules is a good strategy to improve the effect of siRNA-targeted gene silencing. Here, as an RNA expert, BOC Sciences' siRNA chimera customization service can solve your bottleneck problem in siRNA development to a certain extent.
RNA interference(RNAi) is a process involving sequence-specific gene silencing, which mainly involves endogenous non-coding RNA such as microRNA(miRNA), small interfering RNA(siRNA), long non-coding RNA(lncRNA), and cyclic RNA(circRNA) to target and silence messenger RNA(mRNA) in a sequence-specific manner. RNAi has the added advantage of targeting multiple genes with homology at the same time, quickly, economically, and with the potential for site-specific targeting. To be more specific, the primary role of RNAi in cells is to down-regulate the expression of target genes, which in turn down-regulates the expression of the encoded proteins, leading to the desired results. Sequence design and customized siRNA synthesis based on project requirements can circumvent the limitations of conventional therapies, thus providing new ideas for the development of next-generation therapies.
While siRNA has shown promising results in vitro, there are inherent obstacles on the road to achieving gene silencing in vivo and making gene therapy a reality. instability of RNA molecules, low transfection efficiency and half-life, lack of site-specific targeting and distribution in target tissues, and tumor heterogeneity add to the challenges of gene silencing using the RNAi process. Chimeric siRNAs are the preferred strategy to enhance the stability, specificity, or delivery efficiency of siRNA molecules for expanding and optimizing gene therapy applications.
In the case of siRNAs, chimeric molecules can be designed by combining different RNA sequences or incorporating unnatural RNA analogs. In addition, chimeric siRNAs can be designed to have their structures modified, including chemically or by affixing them to other molecules (e.g., peptides, lipids, aptamers, etc.) to improve their targeting and uptake into specific cell types or tissues.
Targeted siRNA delivery using aptamer-siRNA chimeras.(Padmanaban, S.;et al. 2018)
The goal of BOC Sciences is to assist you in designing, synthesizing, customizing, continuously improving and optimizing siRNA chimeras in RNAi process-based therapeutic development studies and projects. Our available siRNA chimera customization services are listed below.
Chemical Method for siRNA | Description | Price |
Bivalent siRNA | Bivalent siRNA designs chimeric molecules by combining different RNA sequences or incorporating unnatural RNA analogs. Bivalent siRNA chimera customization enables efficient delivery of bivalent siRNA chimeras and selective targeting of cells to down-regulate the expression of multiple genes. | Inquiry |
Modified siRNA | Chemically modified siRNAs can significantly improve the efficacy of gene therapy by overcoming poor stability, short half-life, and low cellular uptake. BOC Sciences focuses on providing ribose-, base-, and backbone-modified siRNA modification strategies. | Inquiry |
siRNA Conjugation | The purpose of siRNA splicing is to reduce the targeting effect of the splices and to provide cellular internalization. BOC Sciences offers a wide range of siRNA splicing strategies to choose from, and in collaboration with our siRNA delivery system customization services, your gene therapy development research is sure to be enhanced. | Inquiry |
Specificity: siRNA chimeras ensure selective delivery of siRNA to cells expressing the target molecule, reducing off-target effects.
Enhanced Cellular Uptake: siRNA chimeras can facilitate the internalization of the complex into target cells through receptor-mediated endocytosis.
Therapeutic Potential: siRNA chimeras are expected to serve as targeted therapeutic agents for the treatment of diseases that require regulation or targeting of specific cell types, such as cancer or viral infections.
BOC Sciences has aided many customers with new ideas and advancements in the field of gene therapy, if you need custom Chimera siRNA or more detailed siRNA products and services, please feel free to contact us.
Reference
GMP Oligonucleotide Manufacturing Service
For more than 15 years, BOC Sciences has been manufacturing oligonucleotides for pre-clinical, pharmaceutical, food safety, and animal health industries. We provide customized and flexible oligonucleotide GMP or non-GMP production services to meet different production needs.
Lipid Nanoparticle(LNP) for RNA Delivery
BOC Sciences offers comprehensive LNP- mRNA delivery services tailored to meet the specific needs of mRNA vaccine development. Our expertise in nanoparticle formulation and mRNA chemistry enables us to design custom LNP formulations optimized for stability, efficacy, and safety.
BOC Sciences promises to offer you with GalNAc-siRNA conjugation services to help you conduct further research on GalNAc-siRNA conjugates and explore their mores omnics capabilities, the working mechanism as well as their potential therapeutic profiles.
BOC Sciences offers aptamer customization services to generate high-quality aptamers tailored to your goals, delivering excellent results even for the most difficult target molecules.
Peptide-Oligonucleotide Conjugation
BOC Sciences is committed to providing our customers with comprehensive modification and labeling, offering affordable custom oligonucleotides or peptide-oligonucleotide conjugates.